Drug Profile

Beclometasone intravitreal

Alternative Names: AGN 208 397; Beclometasone intravitreous

Latest Information Update: 19 Dec 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Allergan
Class Anti-inflammatories; Antiallergics; Antiasthmatics; Chlorinated steroids; Corticosteroids; Pregnadienetriols; Small molecules; Vascular disorder therapies
Mechanism of Action Immunosuppressants; Steroid receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Retinal disorders; Retinal oedema

Most Recent Events

08 May 2020 Allergan has been acquired and merged into AbbVie
06 Dec 2018 Discontinued - Phase-I/II for Retinal oedema in Canada, Australia, South Africa, Israel, USA (Intravitreous)
06 Dec 2018 Discontinued - Phase-II for Retinal disorders in Italy (Intravitreous)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com